title: Clinical characteristics related to methotrexate-induced pancytopenia.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohosone
authors.forename: Y
authors.initials: Y
authors.lastname: Okano
authors.forename: H
authors.initials: H
authors.lastname: Kameda
authors.forename: N
authors.initials: N
authors.lastname: Hama
authors.forename: T
authors.initials: T
authors.lastname: Mimori
authors.forename: M
authors.initials: M
authors.lastname: Akizuki
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010198:Pancytopenia / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate